title: Combination of docetaxel and cetuximab for penile cancer:  a case report and literature review.
abstract: Guidelines on the treatment of metastatic squamous cell carcinoma of the penis are limited to a few prospective trials. Cisplatin-based regimens represent the standard of treatment with promising activity of taxanes. Recently, epidermal growth factor receptor overexpression has been shown in these patients. We treated an elderly man with a docetaxel-cetuximab combination after failure of the cisplatin regimen. We observed a necrosis of the inguinal lymph nodes and a reduction of (18)F-fluorodeoxyglucose uptake at PET/CT scan. Only mild mucositis and skin toxicity had been detected. Our case report, the first in the literature, shows that this combination is active and well tolerated in penile squamous cell carcinoma.
authors.affiliation: Genitourinary Oncology and Rare Cancer Center, Federico II University, Naples, Italy.
authors.forename: Pasquale
authors.initials: P
authors.lastname: Rescigno
authors.forename: Elide
authors.initials: E
authors.lastname: Matano
authors.forename: Lucia
authors.initials: L
authors.lastname: Raimondo
authors.forename: Ciro
authors.initials: C
authors.lastname: Mainolfi
authors.forename: Piera
authors.initials: P
authors.lastname: Federico
authors.forename: Carlo
authors.initials: C
authors.lastname: Buonerba
authors.forename: Rossella
authors.initials: R
authors.lastname: Di Trolio
authors.forename: Carmine
authors.initials: C
authors.lastname: D'Aniello
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Damiano
authors.forename: Giovannella
authors.initials: G
authors.lastname: Palmieri
authors.forename: Sabino
authors.initials: S
authors.lastname: De Placido
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000068818:Cetuximab; D000077143:Docetaxel; D004334:Drug Administration Schedule; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D010412:Penile Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D049268:Positron-Emission Tomography; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D019788:Fluorodeoxyglucose F18; D000077143:Docetaxel; D000068818:Cetuximab